Sugi Predict

Sugi Predict / Targets / BCL2L1

BCL2L1

Bcl-2-like protein 1 · Q07817 · BCL2L1 on Sugi Atlas →

136,864 patent compounds predicted against BCL2L1, 91,873 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Abt 737 Abt 737 (SCHEMBL158942) 1.00 18/20
Abt 737 Abt 737 (SCHEMBL170470) 1.00 18/20
SCHEMBL161869 SCHEMBL161869 0.63 13/20
Gingkolic Acid Gingkolic Acid (SCHEMBL163525) 0.95 6/20
SCHEMBL154719 SCHEMBL154719 0.85 6/20
Anacardic Acid Anacardic Acid (SCHEMBL154720) 0.73 6/20
SCHEMBL23277 SCHEMBL23277 0.72 6/20
SCHEMBL105964 SCHEMBL105964 0.61 5/20
Acrylic Acid Acrylic Acid (SCHEMBL111782) 0.60 5/20
Methacrylic Acid Methacrylic Acid (SCHEMBL112437) 0.60 5/20
SCHEMBL97903 SCHEMBL97903 0.59 5/20
SCHEMBL150234 SCHEMBL150234 0.59 5/20
SCHEMBL151609 SCHEMBL151609 0.59 5/20
SCHEMBL161172 SCHEMBL161172 0.55 5/20
SCHEMBL168253 SCHEMBL168253 0.53 5/20
SCHEMBL162389 SCHEMBL162389 0.51 5/20
SCHEMBL107585 SCHEMBL107585 0.51 5/20
SCHEMBL163402 SCHEMBL163402 0.51 5/20
SCHEMBL84570 SCHEMBL84570 0.50 5/20
SCHEMBL169572 SCHEMBL169572 0.50 5/20

Clinical trials — most relevant to BCL2L1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) PHASE3RECRUITING
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML PHASE3UNKNOWN
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia PHASE2COMPLETED
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia PHASE2ACTIVE_NOT_RECRUITING
Safe Accelerated Venetoclax Escalation in CLL PHASE1ACTIVE_NOT_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases PHASE1COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan nanUNKNOWN
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Smoking Influence on Apoptosis in Periodontitis nanCOMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission nanRECRUITING
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL2L1 binder may also engage these)

ProteinNameSimilarity
O77737 — 1.000 O77737 →
Q64373 — 1.000 Q64373 →
P53563 — 1.000 P53563 →
Q07816 — 1.000 Q07816 →
Q91828 — 0.991 Q91828 →
BAX Apoptosis regulator BAX 0.990 landscape →
O02703 — 0.988 O02703 →
O08734 — 0.987 O08734 →
Q6DC66 — 0.987 Q6DC66 →
Q07813 — 0.987 Q07813 →
BAK1 Bcl-2 homologous antagonist/killer 0.984 landscape →
Q63690 — 0.983 Q63690 →
Q7T381 — 0.981 Q7T381 →
Q8R1X6 — 0.981 Q8R1X6 →
Q91827 — 0.980 Q91827 →
Q9JLT6 — 0.980 Q9JLT6 →
Q8JGM8 — 0.980 Q8JGM8 →
Q5EAU9 — 0.980 Q5EAU9 →
Q8N4U5 — 0.979 Q8N4U5 →
Q8BK03 — 0.979 Q8BK03 →
Q69ZZ6 — 0.978 Q69ZZ6 →
A1L2I9 — 0.978 A1L2I9 →
Q5BLE2 — 0.978 Q5BLE2 →
Q1RMX3 — 0.978 Q1RMX3 →
P70444 — 0.978 P70444 →
P84903 — 0.978 P84903 →
Q1JQC5 — 0.978 Q1JQC5 →
Q6GR21 — 0.977 Q6GR21 →
Q99KF0 — 0.977 Q99KF0 →
Q7L4E1 — 0.977 Q7L4E1 →